Regional Guides insights.
Market entry and regulatory strategy by geography
China Clinical Trials: Cost, Speed & Regulatory Advantages
Run clinical trials in China and save 60% on costs with 2-5x faster enrollment. NMPA IND process, MRCT strategy for FDA acceptance, BIOSECURE Act clarification, and China CRO landscape guide.
NMPA Drug Approval Process: Complete Guide 2026
China's FDA equivalent explained. Complete guide to NMPA drug approval pathways, IND filing, Breakthrough Therapy Designation, Conditional Approval, and NDA timelines for global pharma companies.
Top Chinese Biotech Companies to Watch in 2026
The definitive guide to China's most innovative biotech companies with active out-licensing pipelines. ADC, bispecific, GLP-1, CAR-T leaders and their global deal pipelines — organized by therapeutic area.
The BIOSECURE Act: Impact on Pharma Supply Chains & China Partnerships
How the landmark legislation signed December 2025 reshapes global biopharma manufacturing, CDMO relationships, and cross-border deal strategy.
Japan Pharma Market Entry Guide: Navigating the World's 3rd Largest Market
How to enter Japan's ~$90B pharmaceutical market. PMDA pathways, NHI pricing, partnership models, and cultural considerations.
China Biotech Licensing 2026: The Definitive Technical Guide
Navigating the world's second-largest market: From NMPA acceleration to the ADC licensing surge.
The Vision Lifesciences brief.
One email per month. New essays and deal-flow notes from the partner team. Unsubscribe anytime.